AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8923354
Drug: DAB 486IL-2
RxNorm normalized name: DAB(SUB 389)IL2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAB 486IL-2 at 0.075 mg/kg/day
Trial: 24559619
Drug: Finasteride (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (2.5 mg every 3 days for 6 months)
Trial: 19911858
Drug: Prucalopride 4
RxNorm normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Prucalopride 4 mg once daily
Trial: 20529205
Drug: Prucalopride 1
RxNorm normalized name: prucalopride 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prucalopride 1 mg once daily
Trial: 20529205
Drug: Prucalopride 1
RxNorm normalized name: prucalopride 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prucalopride 1 mg and 4 mg once daily
Trial: 20529205
Drug: Prucalopride (1-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prucalopride (1-4 mg once daily)
Trial: 18849320
Drug: Lapatinib (1,250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib (1,250 mg once daily on days 1‐21) plus capecitabine (1,000 mg/m2 every 12 hours on days 1‐14) every 21 days
Trial: 18849320
Drug: Capecitabine alone
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine alone (1,250 mg/m2 every 12 hours on days 1‐14) every 21 days
Trial: 15640411
Drug: CO2 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2 with small added amounts of ioxaglate (200 mgI/mL)
Trial: 14686228
Drug: Prophylactic oral
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic oral ganciclovir therapy
Trial: 10555883
Drug: CDP571 1
RxNorm normalized name: CDP571
DrugBank: Senlizumab (DB17894)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP571 1 mg/kg
Trial: 10555883
Drug: CDP571 10
RxNorm normalized name: CDP571
DrugBank: Senlizumab (DB17894)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP571 10 mg/kg
Trial: 8532768
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment for 1 month
Trial: 1885075
Drug: 5-ASA 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-ASA 1 g enema
Trial: 1885075
Drug: 5-ASA 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-ASA 2 g enema
Trial: 1885075
Drug: 5-ASA 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-ASA 4 g enema
Trial: 31621933
Drug: Edaravone (24-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edaravone (24-week treatment)
Trial: 31621933
Drug: Edaravone (48-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edaravone (48-week treatment)
Trial: 31621933
Drug: Placebo (24-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (24-week treatment followed by edaravone)
Trial: 31621933
Drug: Edaravone (actual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edaravone (actual treatment)
Trial: 30243949
Drug: Group-oriented integrative
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-oriented integrative medicine approach combining dietary intervention and mind-body therapies followed by 8 weeks of telephonic health coaching
Trial: 30243949
Drug: Group-oriented integrative
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-oriented integrative medicine approach
Trial: 28824193
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg diclofenac suppository plus 5 mg isosorbide dinitrate sublingual tablet
Trial: 28824193
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg diclofenac suppository alone
Trial: 16024585
Drug: Almitrine 4
RxNorm normalized name: almitrine
DrugBank: Almitrine (DB01430)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine 4 microg kg(‐1) min(‐1) and inhaled NO 10 p.p.m. (ALM4+NO)
Trial: 16024585
Drug: Almitrine 16
RxNorm normalized name: almitrine
DrugBank: Almitrine (DB01430)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine 16 microg kg(‐1) min(‐1) and inhaled NO 10 p.p.m. (ALM16+NO)
Trial: 12088576
Drug: Extemporaneously syringe-mixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extemporaneously syringe-mixed hepatitis A and B vaccine (Twinrix) and Vi polysaccharide vaccine (Typherix)
Trial: 12088576
Drug: Concomitant administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant administration of hepatitis A and B vaccine (Twinrix) and Vi polysaccharide vaccine (Typherix)
Trial: 8523192
Drug: High-dose tyrosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose tyrosine supplementation (100 mg/kg body weight per day)
Trial: 1950390
Drug: General intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General intensive care treatment and monitoring with a pulmonary artery catheter
Trial: 7134227
Drug: Influenza aluminium
RxNorm normalized name: Aluminium
DrugBank: Aluminium phosphate (DB14517)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Influenza aluminium oxide adsorbate vaccine
Trial: 7134227
Drug: Aqueous vaccine
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous vaccine
Trial: 31696544
Drug: PUR1900 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUR1900 (20 mg)
Trial: 31696544
Drug: Oral Sporanox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Sporanox (200 mg)
Trial: 31696544
Drug: PUR1900 (10-35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUR1900 (10-35 mg)
Trial: 31668569
Drug: Non-MSC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-MSC treatment (prednisone and azithromycin)
Trial: 24814090
Drug: Etrolizumab 100
RxNorm normalized name: pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etrolizumab 100 mg (subcutaneous at weeks 0, 4, and 8, with placebo at week 2)
Trial: 24814090
Drug: Etrolizumab 300
RxNorm normalized name: Etrolizumab
DrugBank: Etrolizumab (DB12189)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrolizumab 300 mg plus loading dose (420 mg at week 0, followed by 300 mg at weeks 2, 4, and 8)
Trial: 24814090
Drug: Etrolizumab 100
RxNorm normalized name: pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etrolizumab 100 mg
Trial: 24814090
Drug: Etrolizumab 300
RxNorm normalized name: Etrolizumab
DrugBank: Etrolizumab (DB12189)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrolizumab 300 mg plus loading dose
Trial: 22266332
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone gel and placebo
Trial: 22266332
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone gel and an aromatase inhibitor
Trial: 19468278
Drug: S(+)‐ketamine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S(+)‐ketamine (2 mg/kg/h)
Trial: 17346020
Drug: Prontosan wound
RxNorm normalized name: PRONTOSAN WOUND GEL BRAUN #400560
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prontosan wound irrigation and Prontosan gel
Trial: 8798100
Drug: Nebivolol 2.5
RxNorm normalized name: nebivolol 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 2.5 mg daily
Trial: 19819787
Drug: Nebivolol 5
RxNorm normalized name: nebivolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 5 mg daily
Trial: 1474161
Drug: Scopolamine 0.2
RxNorm normalized name: scopolamine 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine 0.2 mg
Trial: 1474161
Drug: Scopolamine 0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine 0.08 mg, 0.1 mg, and 0.2 mg; Promethazine 12.5 mg and 25 mg
Trial: 1474161
Drug: Placebo (saline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline, 1 mL)
Trial: 6372084
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg suppositories
Trial: 6372084
Drug: Oxyphenbutazone 250
RxNorm normalized name: oxyphenbutazone
DrugBank: Oxyphenbutazone (DB03585)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxyphenbutazone 250 mg suppositories
Trial: 31927346
Drug: Yoga (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga (12 supervised weekly sessions)
Trial: 26065866
Drug: Direct thrombus
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct thrombus imaging (DTHI) without contrast agent
Trial: 19503764
Drug: N-Acetylcarnosine (1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-Acetylcarnosine (1% NAC) eye drops administered topically for 9 months
Trial: 19503764
Drug: Placebo eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo eye drops administered topically for 9 months
Trial: 16995328
Drug: Echinacea purpurea
RxNorm normalized name: Echinacea purpurea
DrugBank: Echinacea purpurea (DB14239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echinacea purpurea tincture (4 ml)
Trial: 16995328
Drug: Echinacea purpurea
RxNorm normalized name: Echinacea purpurea
DrugBank: Echinacea purpurea (DB14239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echinacea purpurea tablets (12 tablets)
Trial: 16995328
Drug: Echinacea purpurea
RxNorm normalized name: Echinacea purpurea
DrugBank: Echinacea purpurea (DB14239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echinacea purpurea (both preparations)
Trial: 14972468
Drug: Functional Electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional Electrical Stimulation (FES) - 20-Hz square waves at a 300-microsecond pulse duration for 15 minutes twice daily for 1 month.
Trial: 14972468
Drug: Extracorporeal Magnetic
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal Magnetic Innervation (ExMI) - Neocontrol system, 20 minutes twice a week for 2 months, with pulse frequencies of 10 Hz and 50 Hz.
Trial: 9551748
Drug: PAV (8.6+/‐3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAV (8.6+/‐3.6 cmH2O x L(‐1) and 3+/‐1.3 cmH2O x L(‐1)x s(‐1) of volume and flow assistance, EPAP: 1 cmH2O)
Trial: 8068939
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human interleukin-6 (rhIL-6) at doses of 0.5, 1.0, 2.5, 5.0, 10, and 20 micrograms/kg/d
Trial: 8068939
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human interleukin-6 (rhIL-6) at doses starting from 2.5 micrograms/kg/d
Trial: 8068939
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human interleukin-6 (rhIL-6) at doses of 10 and 20 micrograms/kg/d
Trial: 3174723
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (80 mg/daily) for 5 days
Trial: 10931080
Drug: Quinagolide (0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinagolide (0.075 mg/day to 0.6 mg once daily)
Trial: 10931080
Drug: Cabergoline (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline (0.5 mg/week to 1.5 mg twice weekly)
Trial: 2823841
Drug: 1500 IU
RxNorm normalized name: Vitamin E 1500 IU/30 GM Topical application Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 IU low molecular weight heparin (LMWH)
Trial: 2823841
Drug: 2000 IU
RxNorm normalized name: D 2000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 IU low molecular weight heparin (LMWH)
Trial: 2823841
Drug: 2500 IU
RxNorm normalized name: Vitamin A/Vitamin D 2500 IU-270 IU Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2500 IU low molecular weight heparin (LMWH)
Trial: 31929100
Drug: OMT (optimal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMT (optimal medical therapy)
Trial: 30288474
Drug: Maralixibat 70
RxNorm normalized name: Maralixibat
DrugBank: Maralixibat (DB16226)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maralixibat 70 µg/kg/day
Trial: 30288474
Drug: Maralixibat 140
RxNorm normalized name: Maralixibat
DrugBank: Maralixibat (DB16226)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maralixibat 140 µg/kg/day
Trial: 30288474
Drug: Maralixibat 280
RxNorm normalized name: Maralixibat
DrugBank: Maralixibat (DB16226)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maralixibat 280 µg/kg/day
Trial: 30288474
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of maralixibat combined
Trial: 30288474
Drug: Maralixibat (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maralixibat (any dose)
Trial: 23766611
Drug: Topical Steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Steroids
Trial: 17595435
Drug: Parenteral amino
RxNorm normalized name: parenteral amino acid 7 % comb no.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral amino acids at 1.5 g/kg/d for >24 hours
Trial: 17595435
Drug: Parenteral amino
RxNorm normalized name: parenteral amino acid 7 % comb no.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral amino acids at 3 g/kg/d for short (5 hours), extended (24 hours), or prolonged (3-5 days) duration
Trial: 8694986
Drug: Oral-B 35
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral-B 35 toothbrush (Control)
Trial: 2038927
Drug: Saline (0.05,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (0.05, 0.1, 0.2, 0.3 and 0.5 ml)
Trial: 2038927
Drug: Needle insertions
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle insertions using different needle sizes (20 G, 23 G and 30 G)
Trial: 2038927
Drug: Bupivacaine 0.75%
RxNorm normalized name: BUPivacaine 0.75% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.75% (0.1 ml, 30 G needle)
Trial: 2038927
Drug: Bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25% (0.1 ml, 30 G needle)
Trial: 2038927
Drug: Ropivacaine 0.75%
RxNorm normalized name: ROPivacaine 0.75% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.75% (0.1 ml, 30 G needle)
Trial: 2038927
Drug: Ropivacaine 0.25%
RxNorm normalized name: ROPivacaine 0.25%-NaCl 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.25% (0.1 ml, 30 G needle)
Trial: 152937
Drug: No intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intravenous fluids (control group)
Trial: 21949036
Drug: Sanofi‐Aventis branded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sanofi‐Aventis branded enoxaparin (SAe) 40 mg subcutaneously once daily for 7 to 10 days
Trial: 21949036
Drug: eurofarma‐enoxaparin (Ee)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eurofarma‐enoxaparin (Ee) 40 mg subcutaneously once daily for 7 to 10 days
Trial: 7473485
Drug: Oral methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral methotrexate (MTX) after fasting
Trial: 7473485
Drug: Oral methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral methotrexate (MTX) after feeding
Trial: 7473485
Drug: Intravenous methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous methotrexate (MTX)
Trial: 7023520
Drug: Trimeprazine tartrate
RxNorm normalized name: Trimeprazine Tartrate
DrugBank: Alimemazine (DB01246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trimeprazine tartrate 2 mg kg‐1 plus atropine 0.03 mg kg‐1
Trial: 7023520
Drug: Trimeprazine tartrate
RxNorm normalized name: Trimeprazine Tartrate
DrugBank: Alimemazine (DB01246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trimeprazine tartrate 4 mg kg‐1 plus atropine 0.03 mg kg‐1
Trial: 7023520
Drug: Trimeprazine tartrate
RxNorm normalized name: Trimeprazine Tartrate
DrugBank: Alimemazine (DB01246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trimeprazine tartrate 4 mg kg‐1
Trial: 7023520
Drug: Trimeprazine tartrate
RxNorm normalized name: Trimeprazine Tartrate
DrugBank: Alimemazine (DB01246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trimeprazine tartrate 2 mg kg‐1
Trial: 7023520
Drug: Trimeprazine tartrate
RxNorm normalized name: Trimeprazine Tartrate
DrugBank: Alimemazine (DB01246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trimeprazine tartrate 2 mg kg‐1 and 4 mg kg‐1
Trial: 31894037
Drug: Kuntai capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kuntai capsules (4 capsules per time, 3 times a day)
Trial: 31894037
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium enteric‐coated tablets (25mg, 3 times a day)
Trial: 26738329
Drug: Shugan Yiyang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shugan Yiyang Capsules combined with sertraline hydrochloride 50 mg qd
Trial: 26738329
Drug: sertraline hydrochloride
RxNorm normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sertraline hydrochloride 50 mg qd
Trial: 23361162
Drug: 0.4 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 g/kg alcohol (low dose)
Trial: 23361162
Drug: 0.8 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g/kg alcohol (high dose)
Trial: 22506537
Drug: Cinnarizine 20
RxNorm normalized name: cinnarizine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnarizine 20 mg/dimenhydrinate 40 mg (fixed combination)
Trial: 21401214
Drug: Cinnarizine 20
RxNorm normalized name: cinnarizine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnarizine 20 mg (monotherapy)
Trial: 21401214
Drug: Dimenhydrinate 40
RxNorm normalized name: dimenhydrinate 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimenhydrinate 40 mg (monotherapy)
Trial: 16584288
Drug: Fenofibrate (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (250 mg sustained-release capsule) after overnight fasting
Trial: 16584288
Drug: Fenofibrate (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (250 mg sustained-release capsule) after standard breakfast
Trial: 16584288
Drug: Fenofibrate (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (250 mg sustained-release capsule) after high-fat breakfast
Trial: 14563545
Drug: Subutex 2
RxNorm normalized name: Subutex 2mg Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subutex 2 mg
Trial: 14563545
Drug: Subutex 8
RxNorm normalized name: Subutex 8mg Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subutex 8 mg
Trial: 14563545
Drug: Subutex 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subutex 12 mg
Trial: 14563545
Drug: Subutex 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subutex 16 mg
Trial: 14563545
Drug: Suboxone 8
RxNorm normalized name: Suboxone 8/2 Sublingual Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suboxone 8 mg/naloxone 2 mg
Trial: 14563545
Drug: Naltrexone 50-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone 50-150 mg
Trial: 11090789
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg/day for 4 weeks
Trial: 11090789
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 2 weeks followed by Losartan 50 mg/day for 4 weeks
Trial: 8616130
Drug: Chlamydia trachomatis
RxNorm normalized name: CHLAMYDIA TRACHOMATIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlamydia trachomatis IgG antibodies (titre > or = 1/32) in patients
Trial: 8616130
Drug: Chlamydia trachomatis
RxNorm normalized name: CHLAMYDIA TRACHOMATIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlamydia trachomatis IgG antibodies (titre > or = 1/32) in controls
Trial: 15713143
Drug: C. pneumoniae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C. pneumoniae antibodies
Trial: 1329697
Drug: Org 2766
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 2766 (2 mg administered subcutaneously on days 1 and 10 for non-Hodgkin's lymphoma; days 1 and 8 for Hodgkin's disease)
Trial: 1329697
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 mg administered subcutaneously on days 1 and 10 for non-Hodgkin's lymphoma; days 1 and 8 for Hodgkin's disease)
Trial: 6426405
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg/day for 2 years (in premenopausal status, after oophorectomy)
Trial: 6426405
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with mitomycin C 20 mg/m2, iv, followed by cyclophosphamide 60 mg/m2, po
Trial: 6426405
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tamoxifen and chemotherapy
Trial: 6426405
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone or combination of chemotherapy and tamoxifen
Trial: 27759092
Drug: Mild electrical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild electrical stimulation (MES) with heat shock (HS) treatment, 2 treatments per week for 12 weeks